Alterations in maternal and fetal prostaglandin dehydrogenase as a result of maternal ethanol consumption. 1980

S N Pennington, and C P Smith, and J B Strider

Various lines of research have suggested that ethanol consumption may alter prostaglandin-related physiology. Our laboratory has reported that chronic exposure to high doses of ethanol lowers the ability of kidney and lung homogenates from rats to catabolize prostaglandin E2 and F2 alpha via 15-prostagladin dehydrogenase (PGDH). Because of the apparently unique role played by prostaglandins in conception, growth and development of the fetus and parturition, we have attempted to determine if the alterations observed in male rats also occur in females and if any alterations in fetal metabolism result from maternal ethanol exposure. Further, we have measured the influence of ethanol administration on renal clearance of the 15-keto metabolite of PGF2 alpha in an attempt to determine the in vivo significance of the enzyme inhibition observed in vitro. Initial results indicate the following. 1) Female Holtzman rats doses at 2.0, 5.0 and 7.0 mg ethanol/kg during the first, second, and third trimesters of pregnancy, respectively, showed losses in renal PGDH activity similar to those found in males (1.52 versus 1.05 picomole/min/mg, p < 0.001 by matched t-test). 2) Placental tissue (amnion) isolated from these same animals on day 21 of the pregnancies also showed a significant decrease in PGDH activity (14.79 versus 11.77 picomoles/min/mg, p < 0.01). 3) Kidney homogenates from fetuses delivered on day 21 of the pregnancies showed a significant increase in PGDH relative to pair-dosed controls (16.77 versus 12.65 picomoles/min/mg, p < 0.01). 4) In a separate experiment, urinary clearance of PGF2 alpha metabolite was inhibited in a dose related manner up to a level of 6 gm/kg.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D011452 15-Oxoprostaglandin 13-Reductase (5Z)-(15S)-11 alpha-Hydroxy-9,15-dioxoprostanoate:NAD(P)+ delta(13)-oxidoreductase. An enzyme active in prostaglandin E and F catabolism. It catalyzes the reduction of the double bond at the 13-14 position of the 15-ketoprostaglandins and uses NADPH as cofactor. EC 1.3.1.48. Prostaglandin delta-13-Reductase,Prostaglandin-13,14-Reductase,15-Ketoprostaglandin delta 13-Reductase,delta 13-15-Ketoprostaglandin Reductase,delta-13-PG-Reductase,13-15-Ketoprostaglandin Reductase, delta,13-Reductase, 15-Ketoprostaglandin delta,13-Reductase, 15-Oxoprostaglandin,15 Ketoprostaglandin delta 13 Reductase,15 Oxoprostaglandin 13 Reductase,Prostaglandin 13,14 Reductase,Prostaglandin delta 13 Reductase,Reductase, delta 13-15-Ketoprostaglandin,delta 13 15 Ketoprostaglandin Reductase,delta 13 PG Reductase,delta 13-Reductase, 15-Ketoprostaglandin,delta-13-Reductase, Prostaglandin
D005260 Female Females
D005333 Fetus The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN. Fetal Structures,Fetal Tissue,Fetuses,Mummified Fetus,Retained Fetus,Fetal Structure,Fetal Tissues,Fetus, Mummified,Fetus, Retained,Structure, Fetal,Structures, Fetal,Tissue, Fetal,Tissues, Fetal

Related Publications

S N Pennington, and C P Smith, and J B Strider
October 1996, Alcoholism, clinical and experimental research,
S N Pennington, and C P Smith, and J B Strider
January 1982, Developmental pharmacology and therapeutics,
S N Pennington, and C P Smith, and J B Strider
January 1981, Alcoholism, clinical and experimental research,
S N Pennington, and C P Smith, and J B Strider
April 1992, Biochemical pharmacology,
S N Pennington, and C P Smith, and J B Strider
April 1966, Orvosi hetilap,
S N Pennington, and C P Smith, and J B Strider
January 1981, Biology of the neonate,
S N Pennington, and C P Smith, and J B Strider
December 1975, Research communications in chemical pathology and pharmacology,
S N Pennington, and C P Smith, and J B Strider
April 1965, Monatsschrift fur Kinderheilkunde,
S N Pennington, and C P Smith, and J B Strider
January 1976, Annals of the New York Academy of Sciences,
S N Pennington, and C P Smith, and J B Strider
July 1990, Journal of developmental physiology,
Copied contents to your clipboard!